{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:49:52Z","timestamp":1782226192656,"version":"3.54.5"},"reference-count":24,"publisher":"Galenos Yayinevi","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turk Gogus Kalp Dama"],"accepted":{"date-parts":[[2025,7,26]]},"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    This study aims to investigate the infection patterns and antibiotic utilization in critically ill patients receiving extracorporeal membrane oxygenation treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Between January 2019 and January 2024, a total of 165 patients (109 males, 56 females; median age: 58 years; range, 48 to 67 years) who were hospitalized for at least 24 h and underwent extracorporeal membrane oxygenation, and received \u22651 antibiotic treatment in the cardiovascular intensive care unit were retrospectively analyzed. Microbiological culture results, pathogen resistance patterns, antibiotics used, and their doses during extracorporeal membrane oxygenation were evaluated based on the literature and the Sanford Antimicrobial Guide database.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The median number of days spent on extracorporeal membrane oxygenation was 4 (range, 2 to 7) days.\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    (28.8%) and\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (21.1%) were frequently detected in culture results. The median number and duration of antibiotics were 2 (range, 1 to 3) and 2 (range, 1 to 4) days, respectively. Cephalosporins (39%) and penicillins (30%) were the most commonly used antibiotics. At least one antibiotic dose inappropriateness was detected in 56 (33.9%) patients. A total of 366 antibiotic administrations included 73 (19.9%) dose inappropriateness. Continuous renal replacement therapy, sepsis\/septic shock, and extracorporeal membrane oxygenation duration &gt;4 days were identified as risk factors increasing antibiotic inappropriateness (p&lt;0.05).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our study results indicate that patients receiving extracorporeal membrane oxygenation frequently experience antibiotic resistance and the proliferation of Gram-negative bacteria. In our study, antibiotic dosing was inappropriate in approximately one-third of patients receiving extracorporeal membrane oxygenation. Based on these findings, adherence to the literature should be increased while selecting antibiotics and doses for patients.\n                  <\/jats:p>","DOI":"10.5606\/tgkdc.dergisi.2025.27322","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:39:55Z","timestamp":1762857595000},"page":"460-469","source":"Crossref","is-referenced-by-count":0,"title":["Infection and antibiotic patterns in critically ill patients on extracorporeal membrane oxygenation"],"prefix":"10.4274","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-0849","authenticated-orcid":false,"given":"Yunus","family":"Emre Ayhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-9532","authenticated-orcid":false,"given":"Ay\u015fe","family":"G\u00fcl Ko\u00e7o\u011flu K\u0131nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6990-1945","authenticated-orcid":false,"given":"Nilay","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-8177","authenticated-orcid":false,"given":"Nihan","family":"Yap\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012;27:741.e9-18. doi: 10.1016\/j. jcrc.2012.02.013.","DOI":"10.1016\/j.jcrc.2012.02.013"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: A review of the current literature. Clin Ther 2016;38:1976-94. doi: 10.1016\/j. clinthera.2016.07.169.","DOI":"10.1016\/j.clinthera.2016.07.169"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Cheng V, Abdul-Aziz MH, Roberts JA, Shekar K. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J Thorac Dis 2018;10:S629-41. doi: 10.21037\/ jtd.2017.09.154.","DOI":"10.21037\/jtd.2017.09.154"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Ruiz-Ramos J, Gras-Mart\u00edn L, Ram\u00edrez P. Antimicrobial pharmacokinetics and pharmacodynamics in critical care: Adjusting the dose in extracorporeal circulation and to prevent the genesis of multiresistant bacteria. Antibiotics (Basel) 2023;12:475. doi: 10.3390\/antibiotics12030475.","DOI":"10.3390\/antibiotics12030475"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Spriet I, De Waele JJ. Adequate antimicrobial dosing in critically ill patients receiving extracorporeal membrane oxygenation: Where to go from here? Am J Respir Crit Care Med 2023;207:649-51. doi: 10.1164\/rccm.202210-2000ED.","DOI":"10.1164\/rccm.202210-2000ED"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Shekar K, Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Cho YJ, et al. Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation. Am J Respir Crit Care Med 2023;207:704-20. doi: 10.1164\/ rccm.202207-1393OC.","DOI":"10.1164\/rccm.202207-1393OC"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Kim M, Mahmood M, Estes LL, Wilson JW, Martin NJ, Marcus JE, et al. A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation. Crit Care 2024;28:326. doi: 10.1186\/s13054-024-05101-z.","DOI":"10.1186\/s13054-024-05101-z"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Abdul-Aziz MH, Roberts JA. Antibiotic dosing during extracorporeal membrane oxygenation: Does the system matter? Curr Opin Anaesthesiol 2020;33:71-82. doi: 10.1097\/ ACO.0000000000000810.","DOI":"10.1097\/ACO.0000000000000810"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Duceppe MA, Kanji S, Do AT, Ruo N, Cavayas YA, Albert M, et al. Pharmacokinetics of commonly used antimicrobials in critically ill adults during extracorporeal membrane oxygenation: A systematic review. Drugs 2021;81:1307-29. doi: 10.1007\/s40265-021-01557-3.","DOI":"10.1007\/s40265-021-01557-3"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The \u201cOld\u201d and the \u201cNew\u201d antibiotics for MDR gram-negative pathogens: For whom, when, and how. Front Public Health 2019;7:151. doi: 10.3389\/fpubh.2019.00151.","DOI":"10.3389\/fpubh.2019.00151"},{"key":"ref-11","unstructured":"Eucast: Clinical breakpoints and dosing of antibiotics. Available at: https:\/\/www.eucast.org\/clinical_breakpoints [Accessed: 30.12.2024]."},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Gomez F, Veita J, Laudanski K. Antibiotics and ECMO in the adult population-persistent challenges and practical guides. Antibiotics (Basel) 2022;11:338. doi: 10.3390\/ antibiotics11030338.","DOI":"10.3390\/antibiotics11030338"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Hagel S, Fiedler S, Hohn A, Brinkmann A, Frey OR, Hoyer H, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin\/tazobactam to improve outcome in patients with sepsis (TARGET): A prospective, multicentre, randomised controlled trial. Trials 2019;20:330. doi: 10.1186\/s13063-019-3437-x.","DOI":"10.1186\/s13063-019-3437-x"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Worku B, Khin S, Gaudino M, Gambardella I, Iannacone E, Ebrahimi H, et al. Renal replacement therapy in patients on extracorporeal membrane oxygenation support: Who and how. Int J Artif Organs 2021;44:531-8. doi: 10.1177\/0391398820980451.","DOI":"10.1177\/0391398820980451"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Gao X, Wang W. The etiological and drug resistance characteristics of multidrug-resistant pathogens in patients requiring extracorporeal membrane oxygenation: A retrospective cohort study. Infect Drug Resist 2023;16:4929- 41. doi: 10.2147\/IDR.S421413.","DOI":"10.2147\/IDR.S421413"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"K\u00fchn D, Metz C, Seiler F, Wehrfritz H, Roth S, Alqudrah M, et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of Extracorporeal Membrane Oxygenation (ECMO) and renal replacement therapy: A prospective, observational singlecenter study. Crit Care 2020;24:664. doi: 10.1186\/s13054- 020-03397-1.","DOI":"10.1186\/s13054-020-03397-1"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospitalacquired infections: A scientific review. J Appl Microbiol 2021;131:2715-38. doi: 10.1111\/jam.15130.","DOI":"10.1111\/jam.15130"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Li ZJ, Zhang DF, Zhang WH. Analysis of nosocomial \u0131nfection and risk factors in patients with ECMO treatment. Infect Drug Resist 2021;14:2403-10. doi: 10.2147\/IDR. S306209.","DOI":"10.2147\/IDR.S306209"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Shekar K, Fraser JF, Taccone FS, Welch S, Wallis SC, Mullany DV, et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: A matched cohort study. Crit Care 2014;18:565. doi: 10.1186\/s13054-014-0565-2.","DOI":"10.1186\/s13054-014-0565-2"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: An update. Ann Pharmacother 2020;54:43-55. doi: 10.1177\/1060028019865873.","DOI":"10.1177\/1060028019865873"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749-55. doi: 10.1097\/CCM.0000000000000330.","DOI":"10.1097\/CCM.0000000000000330"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010;14:R126. doi: 10.1186\/cc9091.","DOI":"10.1186\/cc9091"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Park J, Shin DA, Lee S, Cho YJ, Jheon S, Lee JC, et al. Investigation of key circuit constituents affecting drug sequestration during extracorporeal membrane oxygenation treatment. ASAIO J 2017;63:293-8. doi: 10.1097\/ MAT.0000000000000489.","DOI":"10.1097\/MAT.0000000000000489"},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang Q, Zhao C, Chen H, Li H, Wang H, et al. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Acinetobacter baumannii complex bacteraemia: Experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network. J Med Microbiol 2020;69:949-59. doi: 10.1099\/jmm.0.001222.","DOI":"10.1099\/jmm.0.001222"}],"container-title":["Turkish Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tgkdc.dergisi.org\/uploads\/pdf\/pdf_TGKDC_4022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tgkdc.dergisi.org\/uploads\/pdf\/pdf_TGKDC_4022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:52:55Z","timestamp":1782222775000},"score":1,"resource":{"primary":{"URL":"https:\/\/tgkdc.dergisi.org\/uploads\/pdf\/pdf_TGKDC_4022.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.5606\/tgkdc.dergisi.2025.27322","relation":{},"ISSN":["2149-8156"],"issn-type":[{"value":"2149-8156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}